BIXT Bioxytran Inc (QB)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 10, 2025

 

BIOXYTRAN, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada		001-35027		26-2797630
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification Number)

 

75 Second Ave, Suite 605, Needham, MA		02494
(Address of Principal Executive Offices)		(Zip Code)

 

617-454-1199

(Registrant’s telephone number, including area code)

 

617-494-1199

(Former Telephone Number, if Changed Since the Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		BIXT		OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01 Other Events

 

On Friday, January 10, 2025, the Company will issue a press-release in reference to a recent pre-print “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients”. authored by Dr. Adesuyi Ajayi (interim CMO), Dr. David Platt (CEO), and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance. Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients.

 

The press-release will be published over Globe Newswire under the title:

 

Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit Number		Description
99.1		Press Release dated January 10, 2025 entitled “Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs”
104	*	Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*	Filed as an exhibit hereto.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	BIOXYTRAN, INC.
	By:	/s/ David Platt, Ph.D.
		David Platt, Ph.D., its Chief Executive Officer
Date: January 10, 2025

 

 

 

Exhibit 99.1

 

Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

 

BOSTON, MASSACHUSETTS, January 10, 2025 — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer’s disease, announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients” (the “Article”) authored by Dr. Adesuyi Ajayi, Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance.

 

Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients http://dx.doi.org/10.13140/RG.2.2.31077.31202

 

The Article discusses the potential of immune checkpoint inhibitors (ICIs) in cancer treatment and explores how galectin-3 modulation might enhance ICI effectiveness. It highlights the importance of overcoming resistance to ICIs and improving patient outcomes by targeting galectin-3, which could increase the objective response rate (ORR) and remission-free survival in oncology patients. Galectin-3 is also a powerful predictive biomarker of ICI failure in Non-Small Cell Lung Cancer (NSCLC) where 90% of patients with high galectin-3 levels failed to see their cancer shrink after 3 treatments. The Article also determined that low to moderate galectin-3 expression in the tumor correlated strongly with a positive response to ICI therapy.

 

ICI resistance due to galectin-3 in the tumor microenvironment is also due to the galectin-3 glycoprotein occupying the antibody’s PD-1 receptor binding site. This was confirmed by Surface Plasmon Resonance (a technique used to study the interactions between molecules by detecting changes in the refractive index near a sensor surface) - and cyrogenic electron microscopy. The galectin-3 protein binds in such a way that it prevents ICI’s from binding to PD-1. This leaves the receptor open to PD-L1 binding which switches off the T-Cells. In vitro tests show that galectin-3 antagonists could reverse this effect.

 

The Company also published its cancer metastasis presentation titled “Galectin Antagonists in Cancer.” The presentation goes over the various ways that cancer tricks the immune system and the current modalities being used to fight cancer. The “Galectin Effect” was highlighted as cancers primary defense mechanism to downregulate and cloak the cancer from immune response. Shortcomings in current treatments are addressed as well as innovative approaches to address the deficiencies. The heart of the presentation shows that galectins play a key role in the tumor microenvironment, promoting tumor growth, metastasis, and immune suppression. Galectin antagonists may hold the key to overcoming these effects and improve efficacy of other cancer treatments.

 

Galectin Antagonists in Cancer

https://tinyurl.com/bdcth9j2

 

“The magnitude of this breakthrough in cancer research cannot be overstated,” said Dr. David Platt, CEO of Bioxytran Inc. “Our findings herald a significant shift in cancer treatment paradigms. We’ve developed a robust theory of cancer and metastasis, identifying Galectin-3 as a pivotal driver of disease progression. This finding elucidates the variable responses in immunotherapy and the development of resistance in other cancer treatments. With over 4,000 peer-reviewed articles examining the role of galectins in cancer, one consensus is clear: they must be inhibited. Our team has synthesized this extensive body of research into the core insights presented in our preprint and cancer presentation. The data unequivocally supports the finding that combining galectin-3 antagonists can significantly enhance treatment response rates.”

 

 

About Bioxytran, Inc.

 

Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran’s molecules achieve virus neutralization. The extent of the carbohydrate structure’s ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com

 

Investor Relations

Michael Sheikh

509-991-0245

mike.sheikh@bioxytraninc.com

 

Forward-Looking Statements

 

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

 

 

v3.24.4

Cover	Jan. 10, 2025
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 10, 2025
Entity File Number	001-35027
Entity Registrant Name	BIOXYTRAN, INC.
Entity Central Index Key	0001445815
Entity Tax Identification Number	26-2797630
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	75 Second Ave
Entity Address, Address Line Two	Suite 605
Entity Address, City or Town	Needham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02494
City Area Code	617
Local Phone Number	454-1199
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	BIXT
Entity Emerging Growth Company	false

---